AVANIR PHARMACEUTICALS INVITES INVESTORS TO LISTEN TO THE CIBC WORLD MARKETS ANNUAL BIOTECHNOLOGY & SPECIALTY PHARMACEUTICALS CONFERENCE WEBCAST

San Diego, March 29, 2006 -- Avanir Pharmaceuticals (AMEX: AVN.R) will be presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Tuesday, April 4, 2006 at 9:30 a.m. ET in New York.  Avanir's President and Chief Executive Officer, Eric Brandt, will be presenting at the investor conference.

The presentation will be available via a live webcast accessible through Avanir's corporate website at www.avanir.com.  To access the webcast, log on to Avanir's site fifteen minutes prior to the presentation to register and download any necessary audio software.  An archive of the presentation will be available until July 4, 2006. 

About Avanir
Avanir Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases.  Avanir's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious diseases.  Avanir previously announced positive results in the second of two required Phase III clinical trials of Neurodex™, an investigational new drug for the treatment of involuntary emotional expression disorder (IEED).  Additionally, Avanir has initiated a Phase III clinical trial for Neurodex as a potential treatment in patients with diabetic neuropathic pain, a second indication for Neurodex.  Avanir has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd., for the treatment of inflammatory disease and AstraZeneca, for the treatment of cardiovascular disease.  The Company's first commercialized product, "abreva®", is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.  Further information about Avanir can be found at www.avanir.com.

Forward Looking Statement

Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate", "anticipate", "believe", "plan", or "expect", or similar statements, are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements.  There can be no assurance that Avanir's new drug application for Neurodex™ will be accepted for filing by the FDA within the anticipated time period or at all; that Neurodex will receive regulatory approval; or that even if such regulatory approval is received, Avanir will be able to market Neurodex successfully.  Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are often unpredictable and outside the influence and/or control of the company.  Risks and uncertainties also include the risks set forth in Avanir's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and from time-to-time in other publicly available information regarding the Company.  Copies of this information are available from Avanir upon request.  Avanir disclaims any intent or obligation to update these forward-looking statements.

Avanir Pharmaceuticals Contacts:

Patrick O'Brien                                                   Patrice Saxon
858-622-5216                                                    858-622-5202
pobrien@avanir.com                                           psaxon@avanir.com

What do you think?
Mar 29, 2006